CN102669649A - Composition for relieving asthenopia - Google Patents
Composition for relieving asthenopia Download PDFInfo
- Publication number
- CN102669649A CN102669649A CN2011100610634A CN201110061063A CN102669649A CN 102669649 A CN102669649 A CN 102669649A CN 2011100610634 A CN2011100610634 A CN 2011100610634A CN 201110061063 A CN201110061063 A CN 201110061063A CN 102669649 A CN102669649 A CN 102669649A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- composition
- parts
- fish
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a composition having application for relieving asthenopia. The composition is prepared by making prepared ocean fish oil, ocean fish polypeptide, vitamin A, vitamin B1, vitamin B2, taurine, and beta-carotene into active ingredients, and then combining commonly-used drug auxiliaries into oral preparation.
Description
Technical field
The present invention relates to a kind of composition, belong to the health food technology field with asthenopia releasing function.
Technical background
The modern society people increase the study and work time, and contact stimulus property environment and light source machine can strengthen, and the time of having a rest reduces, and makes that eye protection is that the mankind improve one of subject matter of sub-health state.Wherein, visual fatigue is comparatively common clinically, is that the subjective symptoms with human eye is main performance, and the syndrome that eye or the organic factor of whole body and mental element are interweaved is so claim kopiopia syndrome again; Visual fatigue mainly shows as: discomfort or pain around eyeball and the eye socket; The acid of the nasion or temples is expanded and is felt; Keep in dark place, shed tears, blurring of vision etc.; Constitutional symptoms such as dizzy, nauseating, vomiting seriously can occur, and normal spiritedness is depressed, energy is not concentrated, failure of memory, insomnia etc., influences people's daily study, work and life.
It is generally acknowledged ametropia and accommodative excess be asthenopic main diseases because of, internal and external environment factors such as light, sound, systemic disease, stress, melancholy and external substance stimulation also with fall ill closely related.Western medical treatment is main with symptomatic treatment at present, adopts neurotrophic agents, sedative or local dripping to use beta-blocker more, a little less than the specific aim, is not suitable for daily health caring and uses with long-term; Use operative treatment, prism rectification, curative effect is comparatively sure, but use face is narrow, and difficult quilt is accepted.
The marine resources finger-type become be present in seawater or ocean in relevant resource, comprise the biology of surviving in the seawater etc., it is extensive that wherein ocean fish oil is applied in health food at present, fish oil is the general designation of the whole oily substances in the fish body, it comprises body oil, liver oil and cerebrol; Fish oil is the byproduct of fish meal processing, and fish and discarded object thereof obtain with separating through steaming, squeezing.The Main Ingredients and Appearance of fish oil is: triglyceride, phosphorus glycerin ether, lipoid, liposoluble vitamin etc.; To from fish-bone, the flesh of fish, fish-skin etc. for the peptide matters that raw material extracts progressively is applied in the health food as efficacy factor at present, what play mostly is enhance immunity, improve effect such as bone density.
Chinese patent publication number CN1544075A open " a kind of Chinese medicine of treating eye illness myopia, elimination visual fatigue symptom and preparation method thereof " is with compositions such as the fruit of Chinese wolfberry, the seed of Chinese dodder, the fruit of glossy privet, the fleece-flowers root; Chinese patent publication number CN101095514A open " a kind of health food with asthenopia releasing function " is made up of cassia seed, cultivated land, Radix Angelicae Sinensis, chrysanthemum, the root of herbaceous peony, the root of Dahurain angelica, Ligusticum wallichii; Chinese patent publication number CN101450098A open " a kind of composition and method of making the same " with asthenopia releasing function,, lutein red by cowberry, vitamin E etc. are formed; Chinese patent publication number CN1583097A open " a kind of have the microcirculation of improvement and alleviate asthenopic health products " is a raw material with the fruit of glossy privet, the seed of Chinese dodder, chrysanthemum, plantain seed.Come haze from present a lot of report documents and invention disclosed patent documentation, relate to the field of Chinese medicines and select the medicine prescription around the prescription or many argument with " liver kidney " of composition of this effect, forming prescription by some in addition is that primary raw material is many with the plant extracts; And the raw material that derives from marine resources and ocean fish is main with fish oil, and the composition of fish oil and the formation of fish polypeptide is not seen.
Summary of the invention
The object of the invention provides a kind of composition, and said composition is to be the rational proportion of ocean fish oil, ocean fish polypeptide and the vitamin of raw material extraction with the ocean fish, and synergy has clear and definite curative effect to alleviating asthenopia.
Alleviating asthenopia composition of the present invention; Select reasonable active principle and component; Wherein the contained phosphatide of deep sea fish oil is indispensable parts such as animal nerve tissue, and also the carrier as fat-soluble A, D and carotenoid etc. promotes vitamin with fat-soluble material absorbing utilization; The marine fish polypeptide is the complex polypeptide that makes for the raw material enzymolysis with the fish, plays fine trophic nerve effect; Taurine is a kind of non-protein amino acid of sulfur-bearing, exists with free state in vivo, has to improve nerve conduction and visual function, regulates crystal osmotic pressure and effect such as anti-oxidant; Vitamin A is the polyenoid alcohol that contains β-root of Dahurain angelica ketone ring, promotes the formation of photopigment in the cellula visualis; Vitamin B1, B2 have the normal effect of the nervous function of keeping.Beta carotene is the precursor of vitamin A, can be converted into vitamin A in vivo, and it has the effect of the lubricated and transparency that keeps cornea.
Characteristics of the present invention are: main component fish oil that this invention composition is a marine fish and fish polypeptide are that primary raw material combines vitamin substances to be directed against eye muscle and optic nerve nutrition is target, are therapeutic purpose to reach alleviating asthenopia; The raw material of this prescription is natural marine product and vitamin, can grow take applied widely.
The material component of the preparation present composition is: deep sea fish oil 1-8 part, marine fish polypeptide 1-15 part, vitamin A 1-30 part, vitamin B1 1-30 part, vitamin B2 1-30 part, taurine 1-30 part, beta carotene 1-30 part are formed.
Preferred for preparation raw material weight component of the present invention is: 2 parts of deep sea fish oils, 12 parts of marine fish polypeptide, 8 parts of vitamin As, Cobastab
18 parts, Cobastab
28 parts, 8 parts of taurines, 4 parts of beta carotenes.
The present composition can adopt conventional method to be prepared into conventional peroral dosage form, like tablet, capsule, oral liquid, electuary etc.
Below in conjunction with embodiment the present invention is done further elaboration:
The Ergonomy evaluation of experimental example 1 present composition
1. clinical data
38 of voluntary participations are divided into treatment group and control group at random.Wherein 20 people are organized in treatment, male 8 people, women 12 people, 13～20 years old age, average 14.8 years old; Control group 18 people, male 8 people, women 10 people, 13～19 years old age, average 15.2 years old.
2. selected condition
1. simple eye or binocular vision checks＜5.0 through logarithmic visual acuity chart;
2. fast computerized optometry behind the mydriasis, diopter between-0.5D～-3.0D;
3. get rid of the organic illness of eye, amblyopia patient and hereditary myopia.
3. instructions of taking
Treatment group: oral present composition preparation, each 1, every day 2 times; Control group: OP (outward appearance, taste and treatment group preparation are roughly the same), every day 2 times; 1 month was 1 course of treatment.Experimenter and inspection doctor are double blinding before finishing the course of treatment.
4. detection method
All experimenters carry out eyesight, slit-lamp, ophthalmoscope, routine blood test, routine urianlysis before taking.After taking the end course of treatment, repeat above-mentioned each item inspection.Before and after all experimenters take, respectively eye symptom is registered, with do not have (0 minute), light (1 minute), in (2 minutes), heavy (3 minutes) classification, and add up with integrated value.
5. criterion:
Subjective symptoms:
Improve: before take (1) integration is arranged, taking the back integration is 0; (2) integration is all arranged before and after taking, but integration deducts and takes back integration >=1 before taking.
Invalid: the identical person of integration before and after take (1); (2) take the back integration greater than integration person before taking.
Visual fatigue symptom decision method (sxemiquantitative integration method)
Annotate: " random thoughts " are meant 1-2 time/2 days; " time have " is meant 1-3 time/day; " often " be meant＞3 times/day eyesights:
Improve (raising): logarithmic visual acuity chart inspection, take improve before the back eyesight is taken 2 row or more than.
Invalid: take the back eyesight take before eyesight do not have to improve or improve and be less than 2 row.
6. the result adds up
Symptom: doing well,improving is added up with integration before and after taking, relatively the checking with T of two groups of sample averages.
Eyesight: eyesight is added up with logarithmic visual acuity chart 5 minutes system before and after taking, relatively the checking with T of two groups of sample averages.
7. result
7.1 take the two groups of clinical symptoms integration statistics in back
T check P＜0.05 before and after the treatment group is taken; T check P＞0.05 before and after control group is taken; Take comparison P＜0.05 of back treatment group and control group.See table 1.
Table 1 liang group clinical symptoms integration
7.2 eyesight
The eyesight raising was less than 2 row, there was no significant difference P＞0.05 before and after control group was taken; The eyesight mean improved more than 2 row before and after the treatment group was taken, and significant difference P＜0.05 is arranged.See table 2.
The comparison that distant vision changed before and after table 2 liang group was taken
Embodiment 1 preparation tablets of the present invention (is example with ten times of material proportional quantities)
Take by weighing each bulk drug by following weight proportion: deep sea fish oil 20 grams, marine fish polypeptide 120 grams, vitamin A 80 grams, Cobastab
180 grams, Cobastab
280 grams, taurine 80 grams, beta carotene 40 grams.
The marine fish polypeptide of above-mentioned weight proportion, vitamin A, Cobastab
1, Cobastab
2, taurine, beta carotene pulverize, and mixes after crossing 100 mesh sieves, progressively adding fish oil is adhesive and auxiliary material granulation, the particle that makes is through whole of 16 mesh sieves; Particle is gone into compressing tablet in the rotary pelleting machine, and every sheet heavily is controlled at 1.0g, and the slice, thin piece that presses sifts out fine powder, picks useless sheets such as loose sheet, sliver, packing.
Claims (6)
1. composition with remitting vision fatigue, it is characterized in that its active component is mainly processed oral formulations by the raw material of following weight portion: deep sea fish oil 1-8 part, marine fish polypeptide 1-15 part are formed.
2. according to the composition of claim 1, form other raw materials of proportioning on the basis, form by deep sea fish oil 1-8 part, marine fish polypeptide 1-15 part, vitamin A 1-30 part, vitamin B1 1-30 part, vitamin B2 1-30 part at it.
3. according to the composition of claim 1; Form other raw materials of proportioning on the basis at it, form by deep sea fish oil 1-8 part, marine fish polypeptide 1-15 part, vitamin A 1-30 part, vitamin B1 1-30 part, vitamin B2 1-30 part, taurine 1-30 part, beta carotene 1-30 part.
4. according to the composition of claim 3, wherein the consumption of each raw material is: 2 parts of deep sea fish oils, 12 parts of marine fish polypeptide, 8 parts of vitamin As, Cobastab
18 parts, Cobastab
28 parts, 8 parts of taurines, 4 parts of beta carotenes.
5. can be used as remitting vision fatigue according to the described composition of claim 1-4 uses.
6. can prepare conventional oral formulations according to the described composition of claim 1-5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100610634A CN102669649A (en) | 2011-03-14 | 2011-03-14 | Composition for relieving asthenopia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100610634A CN102669649A (en) | 2011-03-14 | 2011-03-14 | Composition for relieving asthenopia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102669649A true CN102669649A (en) | 2012-09-19 |
Family
ID=46802736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100610634A Pending CN102669649A (en) | 2011-03-14 | 2011-03-14 | Composition for relieving asthenopia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102669649A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102894367A (en) * | 2012-11-12 | 2013-01-30 | 孟令刚 | Composition containing medlar, xanthophyll and fish oil |
| CN107897930A (en) * | 2017-11-29 | 2018-04-13 | 山东禹王制药有限公司 | One kind improves eyesight, improves presbyopic Halth-care composition, its preparation and preparation method |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100998407A (en) * | 2006-12-29 | 2007-07-18 | 东北虎药业股份有限公司 | Health-care food used for reliefing eyestrain, and its preparing method |
| CN101611894A (en) * | 2008-06-26 | 2009-12-30 | 威海清华紫光科技开发有限公司 | The method of purification of deep sea fish oil and deep sea fish oil fat reducing health product |
| CN101822700A (en) * | 2009-03-04 | 2010-09-08 | 北京因科瑞斯医药科技有限公司 | Medicinal composition with function of alleviating visual fatigue and preparation method thereof |
-
2011
- 2011-03-14 CN CN2011100610634A patent/CN102669649A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100998407A (en) * | 2006-12-29 | 2007-07-18 | 东北虎药业股份有限公司 | Health-care food used for reliefing eyestrain, and its preparing method |
| CN101611894A (en) * | 2008-06-26 | 2009-12-30 | 威海清华紫光科技开发有限公司 | The method of purification of deep sea fish oil and deep sea fish oil fat reducing health product |
| CN101822700A (en) * | 2009-03-04 | 2010-09-08 | 北京因科瑞斯医药科技有限公司 | Medicinal composition with function of alleviating visual fatigue and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 凌关庭主编: "《保健食品原料手册》", 31 January 2003 * |
| 励建荣等: "海洋鱼虾中功能因子的研究", 《食品安全监督与法制建设国际研讨会暨第二届中国食品研究生论坛论文集（下）》 * |
| 无: "吃什么补眼睛", 《绿叶》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102894367A (en) * | 2012-11-12 | 2013-01-30 | 孟令刚 | Composition containing medlar, xanthophyll and fish oil |
| CN107897930A (en) * | 2017-11-29 | 2018-04-13 | 山东禹王制药有限公司 | One kind improves eyesight, improves presbyopic Halth-care composition, its preparation and preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100473406C (en) | Traditional Chinese medicine preparation for eye health care and asthenopia alleviation | |
| CN101505773A (en) | Agent for treating eye diseases | |
| CN104474018A (en) | Health-care soft capsule for relieving asthenopia | |
| CN101897829A (en) | Medicinal composition with function of alleviating visual fatigue and preparation method thereof | |
| CN107375504A (en) | A kind of composition for preventing and treating visual fatigue and preparation method and application | |
| CN103566049A (en) | Composition for improving density of macular pigment in eyes and preventing or treating age-related macular degeneration | |
| CN103110108B (en) | Health-care food with effects of improving eyesight and reinforcing intelligence | |
| CN103798808A (en) | Nutrient formula and application thereof to food or medicine for reliving asthenopia | |
| CN105520137B (en) | It is a kind of that there is the health food alleviated visual fatigue and protect visual function | |
| CN100486456C (en) | Health-care food used for reliefing eyestrain, and its preparing method | |
| CN117562255A (en) | Composition for relieving visual fatigue and preparation method thereof | |
| CN105106286A (en) | Health product with effects of protecting eyes and improving eyesight | |
| CN106692187A (en) | Composition for improving visuognosis persistence and protecting eye health | |
| CN104971304A (en) | Xerophthalmia treatment medicine | |
| CN1973873A (en) | Eye health food capsule | |
| CN102669649A (en) | Composition for relieving asthenopia | |
| CN104147380B (en) | It is a kind of that there is the pharmaceutical composition for alleviating visual fatigue effect, preparation method and application | |
| CN106692259A (en) | Composition for improving glare stimulation | |
| CN105101817B (en) | Edible composition and preparation method thereof and the food comprising said composition | |
| CN101040893A (en) | Blueberry capsule for protecting vision and the preparing method | |
| CN108888682A (en) | A kind of improving eyesight eyeshield composition | |
| CN101856429B (en) | Medicine compound with visual fatigue relieving function and preparation method thereof | |
| CN108991364A (en) | A kind of black pine novel foodstuff and preparation method thereof | |
| CN1123350C (en) | Chinese patent medicine (Tangweiping) for treating eyeground affection of diabetes | |
| CN104587250A (en) | Traditional Chinese medicine eye drops for treating liver and kidney deficiency type myopia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120919 |